Share This Page
Suppliers and packagers for micafungin
✉ Email this page to a colleague
micafungin
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Ph Health | MICAFUNGIN | micafungin sodium | POWDER;INTRAVENOUS | 212156 | NDA | Endo USA, Inc. | 42023-229-10 | 10 VIAL, SINGLE-DOSE in 1 CARTON (42023-229-10) / 10 mL in 1 VIAL, SINGLE-DOSE | 2021-08-01 |
| Ph Health | MICAFUNGIN | micafungin sodium | POWDER;INTRAVENOUS | 212156 | NDA | Endo USA, Inc. | 42023-230-10 | 10 VIAL, SINGLE-DOSE in 1 CARTON (42023-230-10) / 10 mL in 1 VIAL, SINGLE-DOSE | 2021-08-01 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: MICAFUNGIN
Introduction
Micafungin, a semi-synthetic echinocandin antifungal agent, plays a crucial role in treating invasive fungal infections, including candidemia and aspergillosis. As the global demand for effective antifungal therapies rises, the supply chain for micafungin remains a critical component in healthcare. This article explores the leading suppliers, manufacturing landscape, and strategic considerations for stakeholders seeking reliable sources of micafungin.
Overview of Micafungin
Chemical and Pharmacological Profile
Micafungin belongs to the echinocandin class, inhibiting fungal β-(1,3)-glucan synthase, essential for fungal cell wall synthesis. Approved in various markets, including Japan, the US, and Europe, it is administered intravenously primarily in hospital settings. The complex manufacturing process and stringent regulatory standards influence the availability and sourcing options for micafungin.
Major Suppliers of Micafungin
1. Astellas Pharma Inc.
Market Leadership and Global Reach
Astellas Pharma pioneered the development and commercialization of micafungin. Their flagship product, Mycamine, is the first approved micafungin formulation. With a robust manufacturing infrastructure in Japan and North America, Astellas remains the primary global supplier, holding significant market share through its controlled production and distribution channels [1].
Manufacturing Capabilities
Astellas invests heavily in quality assurance and compliance, ensuring consistent supply aligned with international standards such as GMP (Good Manufacturing Practice). The company's lifecycle management focuses on expanding formulations and geographical access, making it a trustworthy supplier for hospitals and pharmaceutical wholesalers.
2. MSI (Meiji Seika Pharma Co., Ltd.)
Regional Focus and Diversification
Meiji Seika, a key Japanese pharmaceutical firm, manufactures micafungin under the brand Myiframe, targeting primarily the Asian market. Their local manufacturing facilities adhere to strict quality standards, and their supply chain is predominantly regional, offering a cost-effective source for domestic market needs [2].
Supply Considerations
While MSI's reach is limited geographically, partnerships and licensing agreements sometimes facilitate broader distribution, especially within Asia and emerging markets.
3. Ajinomoto Pharmaceutical Co., Ltd.
Emerging Market Participant
Ajinomoto has accelerated its pharmaceutical segment, including the production of antifungal agents. Though not as dominant in micafungin specifically, strategic collaborations with established manufacturers have expanded their role in the supply ecosystem, primarily within Japan and select Asian countries [3].
4. Contract Manufacturing Organizations (CMOs)
Third-party Manufacturing
Given the complexity and regulatory requirements, several CMOs specialize in the synthesis and packaging of echinocandin antifungals, including micafungin. These organizations often serve as secondary suppliers or assist in capacity scaling during shortages or surges in demand.
-
Patheon (a Thermo Fisher Scientific company): Offers CDMO (Contract Development and Manufacturing Organization) services, including sterileInjectable formulations.
-
Fujifilm Diosynth Biotechnologies: Specializes in complex molecule manufacturing, including antifungal agents.
These CMOs enable flexibility but rely on primary originator licenses or direct partnerships with companies like Astellas [4].
Supply Chain and Distribution Dynamics
Regulatory Approvals and Market Access
Supply relies heavily on stringent regulatory economies. Countries like the US and EU depend on FDA and EMA approvals, wherein Astellas’ Mycamine holds precedence. Emerging markets often depend on licensing agreements or local manufacturing, impacting supply stability.
Supply Constraints and Shortages
Manufacturing complexity and regulatory hurdles have occasionally led to shortages, prompting reliance on secondary suppliers or generic manufacturers once patents expire or licenses allow. Such scenarios emphasize the importance of diversified sourcing strategies.
Emerging Trends Influencing Micafungin Supply
-
Patent Expirations and Generics: The expiration of patent rights could open opportunities for generic micafungin, increasing supply options but raising concerns about quality and regulatory compliance.
-
Partnerships and Licensing Agreements: Strategic alliances among major pharma firms and CMOs will dictate supply stability and geographic expansion.
-
Manufacturing Innovation: Advances in bioprocessing and fermentation technology may reduce costs and improve scalability, easing supply constraints.
-
Regulatory Harmonization: Efforts to streamline approvals across jurisdictions may facilitate broader distribution channels.
Strategic Considerations for Stakeholders
-
Quality Assurance: Due diligence in verifying regulatory compliance and manufacturing standards is essential, especially when sourcing from CMOs or secondary suppliers.
-
Supply Diversification: Relying on multiple suppliers can mitigate risk, particularly in times of global supply chain disruptions.
-
Market Development: Engaging with emerging markets requires understanding local regulatory pathways and potential licensing arrangements.
-
Monitoring Patent Landscape: Awareness of patent statuses and generic market entries is crucial for strategic sourcing decisions.
Key Takeaways
-
Market Leader: Astellas Pharma Inc. remains the predominant global supplier of micafungin, with significant manufacturing capabilities and distribution networks.
-
Regional Players: MSI and Ajinomoto serve primarily regional markets, offering opportunities in Asia, though with limited global reach.
-
Secondary Suppliers: CMOs play a vital role in capacity augmentation and ensuring supply resilience but depend on primary licensing agreements.
-
Supply Chain Risks: Manufacturing complexities, regulatory hurdles, and patent expirations influence supply stability, underscoring the need for diversified sourcing strategies.
-
Emerging Opportunities: Increasing patent expirations and technological advancements offer pathways for new entrants and generic manufacturers to augment supply.
Conclusion
Strategic sourcing of micafungin demands diligence, leveraging primary suppliers like Astellas, regional manufacturers, and CMOs. Stakeholders should prioritize quality, regulatory compliance, and supply chain resilience to mitigate disruptions. As the antifungal market evolves, so will the landscape of suppliers, demanding ongoing vigilance and adaptive sourcing strategies to ensure uninterrupted clinical and commercial access.
FAQs
1. Who are the primary manufacturers of micafungin globally?
Astellas Pharma Inc. is the leading global manufacturer, with Mycamine being the most widely distributed brand. Regional manufacturers like MSI (Meiji Seika) also produce micafungin, primarily serving Asian markets.
2. How can new entrants access micafungin supply channels?
New entrants typically require licensing agreements with patent holders, partnerships with CMOs, or approval of generic formulations. Ensuring compliance with stringent regulatory standards is crucial for market entry.
3. What factors affect the stability of micafungin supply chains?
Manufacturing complexity, regulatory approval processes, patent statuses, and geopolitical factors significantly influence supply stability.
4. Are generic micafungin products available in the market?
Yes, patent expirations are paving the way for generic versions in some regions, though their availability depends on regulatory approvals and local manufacturing capacity.
5. What are the risks associated with sourcing micafungin from multiple suppliers?
Risks include variability in product quality, regulatory compliance, and pricing differences. Due diligence and adherence to international standards are essential to mitigate these risks.
References
[1] Astellas Pharma Inc. (2022). Mycamine (micafungin sodium) Product Information.
[2] Meiji Seika Pharma Co., Ltd. (2021). Regional Pharmaceutical Portfolio.
[3] Ajinomoto Pharmaceuticals. (2020). Strategic Expansion in Antifungal Agents.
[4] Contract Manufacturing Organizations (2023). Top CDMOs for Complex Injectable Drugs.
More… ↓
